Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4233 - HER2 based expression subpopulations in TNBC: pathological aspects and clinical significance


10 Oct 2016


Poster display


Silvia Mihaela Ilie


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


S.M. Ilie1, C. Desauw2, M. Hebbar3

Author affiliations

  • 1 Medical Oncology, University of Medicine and Pharmacy "Carol Davila", 050474 - Bucharest/RO
  • 2 Medical Oncology, C.H.U. Claude Huriez, 59037 - Lille/FR
  • 3 Oncologie Médicale, C.H.U. Claude Huriez, 59000 - Lille/FR


Abstract 4233


Triple negative breast cancer (TNBC) is defined as hormone receptors less than 1% and human epithelial growth factor receptor 2 (HER2) negative by immunofluorescence. HER2 negative tumors can express an intracellular domain and present a HER2 positive phenotype. Before Trastuzumab era, the prognostic was worse in HER2 over expressed early breast cancer than in triple negative counterpart.


We conducted a retrospective analysis in order to explore the clinical significance of different degrees of tumor HER2 immunohistochemistry expression: 0, 1 or 2 inside triple breast cancer population.


We analysed data from 440 early stage breast cancer patients, primary treated by surgery, addressed to the Department of Medical Oncology of University Hospital of Lille France, for adjuvant chemotherapy, between January 2010 and April 2013. 47 patients (10, 6%) had triple negative phenotype, 67pts (15,2%) HER2 positive, 326 pts (74, 1%) luminal. The mean age was 47 years, 19 %( 9pts) and deleterious BRCA1 or BRCA2 mutations were found in 10 pts (21%). The patients were more likely to have stage IIA 48 %( 23pts), invasive ductal carcinoma 74 %( 35pts), the surgery was conservatory in 28 pts(59,5pts)and the majority, 44pts (93%) was anthracycline exposed. The distribution of HER2 score among TN patients were as follows: 62% (29pts) negative, 27,6 %( 13pts) one plus, 10,4 %( 5pts) two plus and negative for in situ hybridization. HER 2 positivity correlated with pT (p = 0, 05), Ki67 (p = 0, 06) and tumor grade (p = 0, 08). Pathologic stage pT, Ki67, and HER2 score were associated with relapse (p 


The proportion of HER2 positivity inside TNBC population is valuable. The HER2 score 2 correlates with prognostic negative tumor features and associates with poor outcome in our analysis.

Clinical trial identification

Legal entity responsible for the study

University Hospital of Lille France


University Hospital of Lille France


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings